Timber Pharmaceuticals was founded in 2019 to develop treatments for unmet needs in medical dermatology. We have a particular focus on rare diseases or conditions for which there are no current treatments.
Location: United States, New Jersey
Employees: 1-10
Total raised: $500K
Founded date: 2019
Investors 1
| Date | Name | Website |
| - | Altium Cap... | altiumcap.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 06.04.2020 | Grant | $500K | - |
Mentions in press and media 2
| Date | Title | Description |
| 31.03.2023 | Timber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2022 Financial Results | - Lead asset TMB-001 is only compound to receive official orphan drug designation from European Commission for two severe subtypes of congenital ichthyosis, ARCI and XLRI - - Timber has enrolled 50% of patients for pivotal TMB-001 Phase 3 A... |
| 01.10.2021 | Timber Pharmaceuticals : Presents at EADV's 30th Anniversary Congress | Basking Ridge, NJ - (NewMediaWire) - October 01, 2021 - Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of trea... |